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THE EMERGING LOW-DOSE THERAPY FOR ADVANCED CANCERS
Jahangir Satti   Department of Radiation Oncology, Albany Medical Center,
Albany, NY
 Generally minute doses of drugs have been prescribed in biotherapies, homeopathy,
immunization and vaccinations for centuries. Now the use of low doses of drugs is on the
rise to combat serious diseases such as advanced cancers around the world. This new ther-
apeutic approach to address solid tumors and other advanced diseases is a departure from
the conventional use of maximum dose protocol. A small dose of the prescribed drug is
frequently administered in a continuous fashion, at regular intervals, either as a standard
treatment or as a maintenance therapy for a long time. However, this new treatment
method lacks any standard for drug quantization, dose fractionation, repetition frequen-
cy and duration of a treatment course for an individual patient. This paper reviews litera-
ture about metronomic therapy and discusses hormesis: both phenomena occur in low
dose ranges. Better mathematical models, computer simulations, process optimization
and clinical trials are warranted to fully exploit the potential of low dose metronomic ther-
apy to cure chronic and complicated diseases. New protocols to standardize metronomic
dosimetry will answer the age old questions related to hormesis and homeopathy. It
appears that this new low-dose metronomic therapy will have far reaching effects in cur-
ing chronic diseases throughout the world.
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BACKGROUND INTRODUCTION
The chronic diseases are now considered the major causes of physical
disabilities and deaths worldwide. According to a World Health
Organization (WHO) report, the chronic maladies around the world
account for 59% of deaths and 46% for global burden of diseases annu-
ally (WHO 2008). The annual cost of treatment for chronic diseases was
$277 billion and lost productivity reached over one trillion dollars in the
USA alone during 2003. The incidences of chronic degenerative diseases
affect every strata of population around the globe. The rise in cancer inci-
dences has reached an epidemic level in the developing world. Most
developing countries lack finances, infrastructure and expertise either to
diagnose or to treat the advanced degenerative diseases affecting their
growing populations (Bosanquet and Sikora 2004; Chirikos 2002;
Tassinari et al. 2006). Hence there is an urgent demand to explore alter-
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native therapies and methodologies to address the health problems at all
levels across the world. 
Cancer is a hydra-headed chronic malady which produces pathologi-
cal changes in a biological system. Such pathological changes are initiat-
ed at cellular levels. There are over two hundred types of cells in an aver-
age human body. Coincidently, there are about two hundred known types
of cancers among human diseases repertory. A cancerous process may
take at least a decade to grow to a detectable size. The typical predispos-
ing cancer symptoms include melancholia and depression. A physician
would be reluctant to administer any chemical drug or radiation therapy
to a pre-cancerous patient simply because of the severe side effects asso-
ciated with conventional Maximum Tolerable Dose (MTD) protocol.
Furthermore, the above described symptoms may also be found in other
common chronic diseases which do not require prescription of high
chemo or radiation doses. However, conventional treatment approach
toward chronic diseases may change if minimum-dose therapy protocol is
adopted in routine clinical practice at an earlier disease stage. 
A normal living cell inside a healthy body is able to tolerate a hun-
dredfold potent drug dose compared to a single  cell placed in a Petri
dish. An injured cell inside a healthy body tries to repair and heal itself.
An incurable cell is most likely to commit suicide during subsequent cell
division processes. This altruistic behavior among living healthy cells is to
protect the rest of the body from growing unwanted mutated cells. But at
the same time, any living organism cannot evolve and adapt without con-
trolled cellular mutations and differentiations. Hundreds of  cancer
laden mutations take place per day in a healthy normal size human
body(Cameron and  Moulder 1998).
These mutations are essential for the growth of our biological system.
A healthy body cleanses itself of those mutated cells which fail to adapt to
the new temporal-spatial conditions. If unnecessary stimulations repeat-
edly assault a normal cell for a long time and the body fails to adjust with
necessary changes then hyperplasia takes place. A resilient healthy cell
would take on average two to three years before it can develop into a
hyperplastic state. Normally, a healthy system has sufficient time to recov-
er from such mutations within hours. 
Hyperplasia is not detectable with any of our existing diagnostic tools.
If the unwanted stimulatory process continues for an additional two to
three years, then the cell develops into dysplasia. Still it is considered a
precancerous stage, which is not detectable through any existing means.
It will take further two to three years for a dysplastic cell to develop into
an in-situ cancer.
Our current biomedical and biochemical diagnostic tools can detect
a cancerous mass only when it reaches an advanced stage. The conven-
tional non-invasive diagnostic tools to detect cancer consist of ionizing
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and non-ionizing radiations such as x-ray, Magnetic Resonance Imaging
(MRI) and Ultra Sound (US). These diagnostic modalities use tiny parti-
cles/signals/waves which can cross through the living organism and pro-
duce images for analysis. However, these tools fail to detect small size
tumors (Curry III et al. 1990).
The typical resolution of an x-ray image is about 3 millimeters (mm)
in diameter. This x-ray resolving power grows worse in larger structures
such as in the thoracic and pelvic regions where a minimum detectable
size increases to 7 mm in diameter. A typical cancer cell has a diameter of
about 10 micron (μm). It is estimated that there can be millions of can-
cer cells in a 3 mm tumor mass. 
Oncologists have revised the classification of chronic diseases in an
effort to address them at an earlier stage (Rost 2008). This modified early
chronic disease treatment approach will only become possible after new
technologies and low-dose protocols are applied. Today, researchers are
investigating the application of nanotechnology for early diagnosis, drug
processing and delivery of medicine to cure chronic diseases and
advanced cancers in the near future.
The eradication of disease with relatively few side effects is the prime
objective of every physician. Frustrated with conventional MTD out-
comes, now physicians are increasingly resorting to the frequent repeti-
tion of low-dose chemotherapy administered regularly for a longer time.
This methodology is described in the medical literature as Low Dose
Metronomic Therapy (LDMT). It is expected that low-dose strategy may
also produce better outcomes in patients suffering with chronic diseases.
Such diseases, if left uncured at an earlier stage, are likely to progress into
malignancies with the passage of time. Man et al. 2002 had reported the
effectiveness and safety of the chemotherapeutic drug, cyclophos-
phamide at low doses, used on human orthotopic breast or ectopic colon
cancer xenografts in nude or SCID mice. They conjectured that other
drugs at low doses are likely to produce similar beneficial effects with less
toxicity. After finding encouraging results in experimental animals,
Kerbel et al. 2002, wrote an editorial about moving low-dose therapy from
laboratory to clinical trials. Since then scores of research papers have
reported encouraging results produced by LDMT as an anti-angiogenet-
ic therapy in breast cancer patients alone (Colleoni et al. 2005; Colleoni
2006; duManoir et al. 2006; Mancuso et al. 2006).
Recently, Kamat et al. 2007 have studied the effects of low-dose
chemotherapeutic drugs on ovarian cell lines in mouse model. They used
about 60% of MTD of paclitaxel in HeyA8 cells, 50% of the MTD in
SKOV3ipl cells, 6% of the MTD in HUVEC endothelial cell lines and
2.5% of the MTD in MUEC endothelial cell lines.  The docetaxel dose in
LDMT study was 35% and 32% of the MTD in HeyA8 and SKOV3ipl cell
lines respectively. The use of docetaxel in endothelial cell line was only
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2% for HUVEC and 6% for MUEC respectively. They have reported excel-
lent clinical results and insignificant toxicity with LDMT in their experi-
ment (Kamat et al. 2007). 
The low-dose chemotherapeutic research for cancer patients began
in 1972. All major pharmaceutical companies were involved in research
and development of anti-angiogenetic drugs by 2002 (Brower, 2003). The
strategy in anti-angiogenetic therapy is to attack the cancer-feeding
endothelial vasculatures as well as the solid tumor itself. Gasparini has
conducted scientific debate on the strategy, drug development and clini-
cal indications for anti-angiogenetic agents and their scheduling
(Gasparini, 1997, 2001). 
Those physicians who seek the best care for their patients habitually
keep themselves abreast of new findings. Such physicians in cancer care
are gradually gearing toward this new low-dose methodology. By evaluat-
ing the positive early findings of anti-angiogenesis model, Miller has pro-
jected significant beneficial impacts to treat breast cancer with low dose
therapy in routine clinical practice (Miller, 2004). Benefits related to low-
dose chemo as a maintenance therapy for a long period of time has been
reported in clinical practice (Munoz et al., 2005). There have been
reports of superior results with smaller doses in advance metastatic breast
cancers, too (Munoz et al. 2006). A description about angiogenesis can be
found in reference (Folkman, 2003).
Low-dose chemotherapy has been documented as an efficacious
modality in ovarian cancers (Kamat et al. 2007; Garcia et al. 2008). Franchi
et al. 2007 have reported that repetition of low-dose cancer drugs contin-
uously for some time has low toxicity. They observed low toxicity associ-
ated with metronomic therapy in those patients suffering with advanced
cancer who refused the aggressive standard therapies (Franchi et al.
2007). They urged an evaluation of the low-dose system and questioned
the benefits of existing high-dose strategy over it. After critical analysis,
Baruchel and Stempak, 2006, have concluded that low-dose metronomic
chemotherapy is a clinical reality in the making.
Low-dose therapy acts as a double-edge sword against cancer: it
attacks both the tumor-feeding endothelial vasculatures and the solid
tumor.  Shimizu and Oku, 2004, have reported that metronomic therapy
spans over different phases of diseases which exist in precancerous states
in human organism.
LESS IS MORE BUT HOW MUCH LESS?
Specific research in cancer has discovered the promising beneficial
effects of micronutrients found in spices, herbs, conventional drugs and
common foods. However, the correct dose, either as chemopreventive or
therapeutic, has remained elusive to the scientific community. Scientists
have found in various cancer research studies that small doses of
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chemotherapy administered for a long period of time showed promising
results in mouse models (Hanahan et al. 2000; Kamen et al. 2000; Kamen,
2005; Kamen, et al. 2006; Piccart-Gebhart, 2003). Young et al. 2006, have
reported that low dose combination therapies proved beneficial in vari-
ous advanced solid tumors with minimal toxicity to patients.
Unfortunately, there is no “minimum-dose” standard defined for chemi-
cal drugs or ionizing radiation in medical literature. This is due mainly to
the multiphase dose response in living organisms. One such example is
arsenic trioxide (As2O3), now a standard chemotherapeutic drug used to
treat Acute Promyelocytic Leukemia (APL). Interestingly, the drug is now
being tested to treat other solid tumors. Arsenic Trioxide, like many other
drugs, produces multiphase effects in cancer patients (Liu et al. 2006).
Bertolini et al. 2003, have reported that As2O3 produces opposite effects
on circulating endothelial progenitor cells when used at concentrations
of MTD and LDMT.
Earlier, Bocci et al. 2002, pointed out that low-dose As2O3 has differ-
ent narrow windows of actions in varied concentrations for human
endothelial cells. Arsenic trioxide can either promote or inhibit angio-
genesis, based on the amount of the dose (Soucy et al. 2003, Snow et al.
2005). We do know there exists a narrow window for each drug to pro-
duce specific reactions in a particular living organism. In that cancer cells
are not an integral part of the natural organization of a living system, they
respond differently to different stimulus, such as heat or specific doses of
a drug. Below a specific dose, the cancer cells cease to respond. Such a
study has been conducted by Walchli, et al. 2006 in which they have found
normal primary lymphocytes responded to highly diluted homeopathic
remedies, whereas, cancerous lymphocytes did not respond to such dilu-
tions at all.
NANO PARTICLES
Drug-induced effects on living organisms can be further enhanced by
modifying the drug manufacturing methods. New manufacturing
processes can improve the bioavailability of active ingredients, even at
lower drug concentrations. Such techniques can also enhance the bio-
logical effects, even with smaller doses. These novel strategies are likely to
introduce new challenges to low-dose therapies. One such drug manu-
facturing process is based on nano technology. The nano particles are dis-
tributed over a wide area, which improves their surface chemistry for
optimal reactions—proving to be much greater compared to bulk-scale
chemicals. Fukai et al. 2006 have reported that As2O3 at nano-molar con-
centrations, as opposed to micro-molar, is sufficient to produce signifi-
cant therapeutic effects in APL cells, provided other natural sources of
arsenic, such as found in seafood, are restricted for a few days (Fukai et al.
2006). It is interesting to note that such dose-dependent multiphase bio-
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logical reactions are not limited to particular chemical drugs. Dose-
dependent dual effects have also been found in common herbal medi-
cine (Barajas-Farias et al., 2006, Jimenez-Medina et al., 2006).
The resolution of a correct chemical concentration of a drug in low-
dose chemotherapy is a challenge to both researchers and clinicians. Lam
et al. 2006 have called on the scientific community to develop tangible sci-
entific methodologies for metronomic therapy. They fear that mere sim-
ple empiricism may give rise to skepticism (Lam et al. 2006). The issue of
dose strength becomes more complicated when combination drugs are
used in cancer treatment. Yap et al. 2005 have showed that complement-
ing various cancer drugs in small doses can produce optimal treatment
results in mice, modeled after prostate cancer. Cancer researchers have
also found that a combination of chemotherapy bolus dose and low oral-
dose treatment makes the best strategy to combat cancer on a long-term
basis in a human melanoma grown subdermally in nude mouse model
(Shaked et al. 2005a). 
Maraveyas et al. 2005 have questioned if any rationale dose strength
can be designed for small-dose therapy. Drug quantization for low-dose
therapy is the core problem because a multitude of biological reactions,
such as stimulation, feedback, compensation, apoptosis, etc., have very
narrow windows specific to individual constitution and the chemical con-
centration of a particular drug in the low-dose region. The search for
optimal low-dose drug standardization is an ongoing unsettled issue in
the medical community (Adjei, 2006). 
ANTI-ANGIOGENESIS
An alternative approach to treat cancer is to attack the endothelial
vasculature, which supplies nutrients to a tumor. This approach also
requires smaller drug doses, compared to conventional MTD protocol.
Shaked et al. 2005b have proposed the optimal dose associated with angio-
genetic activity. The anti-angiogenetic therapy is claimed to be safe. It
does not seem plausible that anti-angiogenetic therapy is absolutely free
of any side effects. This strategy has its own shortcomings, due mainly to
a time-dose fractionation schedule and the amount of dose of a particu-
lar drug appropriate to an individual patient. Chemotherapeutic drugs
produce coagulation as an unwanted side effect in an antiangiogentic
therapy.  Ma et al. 2005 have expected that the use of low-dose chemother-
apy would reduce the incidence of adverse clotting effects. Rozados et al.
2004 have claimed that low dose chemotherapy produced regression in
rat tumors without any toxicity. But De Pas et al. 2005 have recommend-
ed an extensive study to ascertain the long-term real effects in metro-
nomic therapy. Emmenegger et al. 2004 produced a detailed comparison
of toxic effects between LDMT and MTD for Cyclophosphamide on high-
ly sensitive tissues.
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BEYOND HORMESIS
Hormesis is defined as the low-dose stimulatory and high-dose
inhibitory processes observed in biological systems. An extensive litera-
ture database comprising hormesis is available in research journals and
on the Web. As of June 10, 2008, the PubMed database search, contain-
ing the name “hormesis” returned 572 papers in medical journals. The
word ”metronomic” in the same database yielded only 210 published arti-
cles. Like metronomic therapy, hormesis occurs in low-dose radiation
energies and chemical concentrations. 
Unlike hormesis, low-dose metronomic therapy is a new concept with
claims of better effects, few to no side effects, and inexpensive. It is
expected to radically change the practice of medicine related to chronic
diseases in the future. Both metronomic therapy and hormesis take place
in the low-dose chemical regions. Hormesis is generally considered a
biphasic biological phenomenon that can result from stimulatory, com-
pensatory, feedback or simple cellular repair processes (Calabrese, 2004).
On the other hand, a different set of diseases requires a different mode
of cellular reactions to heal a sick body. For example, an immune-stimu-
lating process may be needed to heal an infection or cancer. On the other
hand, immune boosting is usually discouraged in auto-immune diseases
such as rheumatism. A cellular compensatory process may be deemed
necessary to repair endocrinal systems.
It has been observed that a living organism develops resistance
through different reactive mechanisms after being exposed to subtoxic
doses of radiation and chemicals (Macklis and Beresford, 1991, Davies et
al. 2006). Evolution of such a biological robustness in a living system is
possible at different levels, i.e., DNA to organ levels. Minute amount of
viruses can stimulate the DNA, which in turn affects the cell, organ and
subsequently the entire body. Biological reactions induced with subtoxic
doses are the multiphase stimulatory processes which result from inter-
action between the body's cellular systems and the energy supplied by a
drug interaction or radiation exposure. The exact dose of a particular
chemical to induce a specific kind of reaction in a particular biological
system has not yet been quantified in scientific literature. It appears that
diseases involving sluggish biological reactions are most likely to benefit
from the biological reactive phenomenon such as hormesis. However,
classification of such diseases, the health status of an individual, the
amount of drug, its possible mode of administration and the expected
stimulatory processes and their possible outcomes must be spelled out in
concrete research settings. 
On the other hand, hormetic effects induced by common foods are
undisputedly recognized as health benefits in the scientific community
(Mattson and Cheng, 2006). Hormetic benefits have also been realized in
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subjects under stress, annoyance and noise (Rylander, 2004). Such bene-
ficial effects are due to cellular compensatory responses to external stim-
ulus. Again, the nature of cellular reaction depends on the amount of
dose, time of administration, biological status of the organism and the
previous levels of exposure to same or similar stimulants. 
Hormetic benefits induced in one cell can also produce useful effects
in bystander cells. Similarly, stimulation of one system can produce cer-
tain effects in another connected system in an integrated environment
such as the human body. For example, any improvement in the respira-
tory system can enhance the cardiovascular efficiency by virtue of elevat-
ed oxygen uptake in the alveoli. This can lead to an efficient production
and utilization of energy at the (w)holistic level. In a nutshell, bio-effects,
such as hormesis, deserve due attentions as their unique integrated
dynamical effects on living organisms can help heal the chronic diseases
with less toxicity to the ailing body. Cuttler 2007 has rightly questioned
the common sense for ignoring the role of low-dose effects on living
organism. But realization of such a new approach to heal the sick in an
established conventional medical practice is an uphill battle. 
Biological effects based on nonlinear dose-response models, such as
in hormesis, have been under severe criticism by various groups for a vari-
ety of reasons. Such a stereotypical attitude toward hormesis has so far
made it unlikely to form the foundation of low-dose therapy in its present
form (Thayer et al. 2005, Mushak, 2007). However, such an attitude is like-
ly to change in the era of emerging metronomic therapy. The low-dose
issue poses a great challenge to define the drug-dose decision for clinical
practice, especially in metronomic therapy (Thayer et al. 2005, Lutz et al.
2005). Some of the information about cell stress and hormesis at molec-
ular levels is well known but their concrete utilization in routine clinical
practice has thus far been elusive (Agutter, 2007).
It appears there is an overlap of dose response between hormesis phe-
nomenon and metronomic therapy in that both occur in the low-dose
regions, as defined by the MTD standards. Standardization of drug-dose
protocol for metronomic therapy will greatly pave the way toward recog-
nizing the beneficial effects of hormesis in a biological system. A team of
researchers have tried to scientifically elaborate hormesis with reference
to dose-response phenomenon (Calabrese and Blain, 2005; Calabrese et
al. 2007).  There are many unanswered questions, such as time-dose frac-
tionations, when it comes to applications of hormesis in routine clinical
practice. Calabrese 2007 has expressed a great deal of frustration at the
absence of such a clear-cut dose demarcation and lack of quantitative
models in hormesis.
Calabrese and Baldwin 1998 have proposed hormesis as a possible
biomedical hypothesis in a rigorous fashion. Cancer can also be initiated
due to continued stimulatory processes, which generate multiple muta-
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tions in  single or multiple cells. Kinoshita et al. 2006 have discussed the
implications of hormesis in carcinogenesis.  This murky area needs crys-
tal clear analytical foundations to develop a drug dose-based effective
therapy for routine clinical practice. Stumpf 2006 has correctly pointed
out it is not a linear issue. Doses differ quantitatively and qualitatively in
their actions on a living organism. There is no lack of enthusiasm to uti-
lize the hormetic phenomenon in clinical practice. Yun et al. 2005 have
hypothesized to utilize the compensatory response of cells to treat chron-
ic diseases. All the objectives require a comprehensive planning frame-
work at pharmaceutical, biological, therapeutic and clinical levels. 
CONCLUSION
The research database concerning continuous administration of low-
dose chemotherapy reveals compelling evidence of its effectiveness and
superior clinical results in cancer patients.
The use of low-dose chemotherapy for advanced cancers is on the
rise. The main reasons, among others, for the new strategy are its report-
ed effectiveness, alleged little to no toxicity and relative economic bene-
fits (Bocci et al. 2005). The biological responses at low doses are known to
the scientific community in the form of hormesis, homeopathy, immu-
nization and vaccination practices. The drug concentrations in homeop-
athy can be extremely small, which sometimes lead beyond the possibili-
ty of finding a single drug atom or molecule in an entire bottle.
Furthermore, there is no established drug standardization metric for its
dilutions in homeopathy (Satti, 2005). However, homeopathic drugs are
intended to produce reactions in a sick person. Such a reaction can be
initiated with extremely small amounts. Hormesis, on the other hand, is
a biological reaction that can also be initiated in a normal healthy system
(Chen et al. 2006). A potent dose of a drug is required to produce any
reaction in a healthy system. The dose can be more potent than the drug
dose used in homeopathy. The normal amount of drug dose used in
metronomic therapy must be sufficiently potent to kill an unwanted can-
cer cells. However, such drug-dose concentration is much less than the
MTD. It appears that the dose concentration levels in hormesis and
LDMT are comparable or overlap considering their similar actions at cel-
lular levels.
The current trend of using low-dose therapy in advanced cancers is
likely to steadily rise in the future because of its effectiveness, low toxici-
ty and affordability. But the issues of time-dose fractionation are still
greatly unresolved. A great deal of scientific literature is available about
low dose effects, commonly known as hormesis. There is a need to devel-
op new models, conduct simulations and run clinical trials to fully exploit
the low-dose potential against chronic diseases, especially cancer.
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